Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
RADX
Radiopharm Theranostics Limited
Theranostic radiopharmaceuticals using radiolabeled ligands for targeted cancer therapy.
|
$32.22M |
$5.30
+0.76%
|
|
POCI
Precision Optics Corporation, Inc.
The business includes design and manufacture of components/subassemblies for medical devices, i.e., Medical Device Components.
|
$32.12M |
N/A
|
|
JSPR
Jasper Therapeutics, Inc.
Core product briquilimab is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$31.55M |
$2.09
-8.33%
|
|
QTTB
Q32 Bio Inc.
Bempikibart is a fully human monoclonal antibody targeting IL-7Rα, a core monoclonal antibody therapeutic category.
|
$31.35M |
$2.58
-8.19%
|
|
MYO
Myomo, Inc.
MyoPro is a prosthetic upper-limb device designed to replace or assist movement for partially paralyzed limbs, fitting Prosthetics & Implants.
|
$31.22M |
$0.85
-8.09%
|
|
BOLD
Boundless Bio, Inc.
The company is a biotechnology firm focused on oncology, developing ecDNA-directed cancer therapies, which places it in Biotech - Oncology.
|
$30.67M |
$1.39
-1.07%
|
|
SABS
SAB Biotherapeutics, Inc.
Company focuses on immunology therapeutics using DiversitAb platform to generate fully human polyclonal antibodies.
|
$30.20M |
$3.25
-0.15%
|
|
PRPO
Precipio, Inc.
Pathology/clinical lab services and diagnostic testing operations.
|
$30.19M |
$20.83
+1.61%
|
|
DRIO
DarioHealth Corp.
Integrated Medical Devices & Biometrics (smart glucose meters and biofeedback sensors) are part of the offering.
|
$30.19M |
$14.01
+0.14%
|
|
MODD
Modular Medical, Inc.
MODD directly manufactures insulin pumps (MODD1 and Pivot), a core medical device product category categorized under Medical Devices & Biometrics.
|
$30.17M |
$0.55
+10.73%
|
|
BDMD
Baird Medical Investment Holdings Limited
BDMD is a medical device manufacturer focused on microwave ablation systems and related hardware, a core medical devices category.
|
$29.92M |
$1.20
-8.40%
|
|
TENX
Tenax Therapeutics, Inc.
TNX-103 levosimendan is a cardiovascular drug candidate in Phase 3 for PH-HFpEF, making Cardiovascular Drugs the direct product category.
|
$29.74M |
$7.12
-3.07%
|
|
RBOT
Vicarious Surgical Inc.
The company directly manufactures and sells surgical equipment in a robotic system for minimally invasive surgery.
|
$29.42M |
$4.96
-6.94%
|
|
IBIO
iBio, Inc.
The company markets and utilizes an Antibody Discovery Platform (epitope-steering AI, StableHu, EngageTx, ShieldTx) to identify and optimize antibody candidates.
|
$29.07M |
$1.75
+9.06%
|
|
TLPH
Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
|
$28.91M |
$1.40
+4.48%
|
|
PLUR
Pluri Inc.
Directly related to placenta-derived cell therapy products PLX-PAD/PLX-R18 and the company's 3D cell expansion platform used for cell therapies.
|
$28.90M |
$3.99
+2.31%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
Ketamir-2 is a novel oral small-molecule therapeutic targeting neuropathic pain, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$28.76M |
$1.73
+3.29%
|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$28.71M |
$2.48
+13.24%
|
|
QDMI
QDM International Inc.
Health/medical insurance products are distributed via the company’s insurance brokerage activities.
|
$28.70M |
$17.00
|
|
BMGL
Basel Medical Group Ltd Ordinary Shares
BMGL provides hospital-style healthcare services, including inpatient/outpatient care via clinics and integrated care delivery.
|
$28.61M |
$1.53
+1.32%
|
|
NXTC
NextCure, Inc.
NextCure's lead programs are Antibody-Drug Conjugates (ADCs), the core product modality of the company.
|
$28.00M |
$11.71
-7.10%
|
|
RLYB
Rallybio Corporation
Core focus on rare diseases with lead and preclinical assets addressing complement dysregulation and iron overload.
|
$27.80M |
$0.67
-4.62%
|
|
NERV
Minerva Neurosciences, Inc.
Minerva focuses on neuropsychiatric drug development (roluperidone for schizophrenia negative symptoms).
|
$26.71M |
$3.84
-8.57%
|
|
XCUR
Exicure, Inc.
GPCR USA's lead asset GPC-100.00 is an oncology biotech product in development, representing the core biotech asset.
|
$26.60M |
$4.15
-5.68%
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal's tecarfarin is described as a novel oral small-molecule therapeutic, directly aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$26.53M |
$13.30
-2.67%
|
|
RVP
Retractable Technologies, Inc.
Core product category directly manufactured and sold: passive-safety syringes designed to prevent needlestick injuries.
|
$26.37M |
$0.86
-2.03%
|
|
CLGN
CollPlant Biotechnologies Ltd.
rhCollagen is a recombinant protein, and CollPlant's core product is plant-derived recombinant human collagen used in implants, fillers, and bioinks.
|
$26.12M |
$2.21
+2.55%
|
|
ITRM
Iterum Therapeutics plc
ORLYNVAH is an oral small molecule antibiotic (sulopenem) that the company is launching commercially.
|
$26.07M |
$0.66
-1.51%
|
|
WETH
Wetouch Technology Inc.
Medical applications revenue suggests involvement as a component provider in medical devices, i.e., Medical Device Components.
|
$25.89M |
$2.17
-12.65%
|
|
NSYS
Nortech Systems Incorporated
Medical Device Components manufacturing and assembly for regulated markets.
|
$25.86M |
N/A
|
|
HBIO
Harvard Bioscience, Inc.
HBIO generates recurring revenue from consumables used with its medical devices and bioproduction platforms (biochips, reagents, etc.).
|
$25.38M |
$0.57
+10.05%
|
|
NXL
Nexalin Technology, Inc.
Core product is non-invasive neuromodulation devices for brain stimulation (Gen-2 SYNC, Gen-3 HALO).
|
$25.25M |
$1.48
-1.67%
|
|
KPEA
Kun Peng International Ltd.
The business includes health care equipment-based services and devices, aligning with medical devices & equipment.
|
$25.16M |
$0.06
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$24.92M |
$0.64
-3.56%
|
|
GDTC
CytoMed Therapeutics Limited
Core business platform focuses on cell-based immunotherapies (gamma delta T cells, NK cells), aligning with Biotech - Cell Therapy.
|
$24.41M |
$2.28
+3.64%
|
|
XFOR
X4 Pharmaceuticals, Inc.
Company develops therapies targeting rare immune disorders (WHIM syndrome, CN), fitting Biotech - Rare Diseases.
|
$23.68M |
$4.08
+1.11%
|
Showing page 31 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
